SummaryInterferon α (IFNα) is a prompt and efficient orchestrator of host defense against nucleic acids but upon chronicity becomes a potent mediator of autoimmunity. Sustained IFNα signaling is linked to pathogenesis of systemic lupus erythematosus (SLE), an incurable autoimmune disease characterized by aberrant self-DNA sensing that culminates in anti-DNA autoantibody-mediated pathology. IFNα instructs monocytes differentiation into autoinflammatory dendritic cells (DCs) than potentiates the survival and expansion of autoreactive lymphocytes, but the molecular mechanism bridging sterile IFNα-danger alarm with adaptive response against self-DNA remains elusive. Herein, we demonstrate IFNα-mediated deregulation of mitochondrial metabolism and impairment of autophagic degradation, leading to cytosolic accumulation of mtDNA that is sensed via stimulator of interferon genes (STING) to promote induction of autoinflammatory DCs. Identification of mtDNA as a cell-autonomous enhancer of IFNα signaling underlines the significance of efficient mitochondrial recycling in the maintenance of peripheral tolerance. Antioxidant treatment and metabolic rescue of autolysosomal degradation emerge as drug targets in SLE and other IFNα-related pathologies.
Germinal centers (GC) are the predominant origin of human B cell lymphomagenesis. Transgenic mice in which gene expression is altered specifically in GC B cells have broadened our knowledge about the mechanisms of malignant transformation. However, extensive resources are needed due to the genetic complexity of these mouse models. Thus, bone marrow (BM)-derived chimerism is an attractive approach to study GC B cell derived lymphomagenesis, as it allows for an efficient allocation of resources and reduces the number of animals used.
Background/Objectives In SLE circulating IFNa can induce peripheral blood monocytes to differentiate into dendritic cells with increased MHCII antigen presenting capacity. Monocytes’ differentiation and self-antigen presentation has been shown to depend on autophagy, the catabolic degradation of unnecessary/dysfunctional cellular components and organelles and relies on the cooperation of autophagosomes with lysosomes. Our aim was to delineate the role of autophagy in shaping the autoreactive phenotype of SLE monocytes upon IFNa signalling and to dissect the underlying mechanism. Materials/Methods Serum and peripheral blood CD14+ monocytes were isolated from active, newly diagnosed or off-treatment SLE patients (n = 20) and age and sex matched healthy donors (n = 18). Autophagy, both spontaneous and following incubation with SLE serum (10%) or rhIFNa (104U/ml), was assessed by immunoblotting and confocal microscopy for LC3 and P62. ATG5 and P62 mRNA levels were assessed by QPCR. Autophagy induction was inhibited by wortmanin or 3MA and autophagy completion was inhibited by hydroxychloroquine. Rapamycin and LPS were used as autophagy inducers. Healthy monocytes were treated with SLE serum or rIFNa and their antigen presenting capacity was assessed by flow cytometry for HLA-DR, CD86 and CD40. Alterations in autophagolysosomal pH were assessed by confocal microscopy (Lysotracker Red-DND99). ROS production was measured using DCFHDA and mitochondrial polarisation was assessed by MitotrackerRed CMXRos and JC1. Results SLE monocytes exhibited increased levels of Atg5 mRNA (3 ± 0.5 fold increase, p < 0.05) and lipidated LC3B protein (p < 0.005) compared to healthy controls. Notably, autophagosomal P62 degradation was defective in SLE and this coincided with defective lysosomal acidification. Treatment of healthy monocytes with SLE serum or rIFNa recapitulated the abnormalities observed in SLE monocytes as for ATG5 transcription (p < 0.005), LC3B lipidation (p < 0.05), defective autophagosomal P62 degradation (p < 0.05) and defective lysosomal acidification. Importantly, in both SLE monocytes and healthy monocytes treated with rIFNa, mitochondria were found hyperpolarized and ROS production was increased. Enhanced antigen presenting capacity upon SLE serum or IFNa treatment was autophagy dependent as evidenced by autophagy manipulation experiments. Conclusions Monocytes from SLE patients display enhanced autophagy induction, driven by soluble factors such as IFNa. Autophagy completion is disrupted and this coincides with the presence of uncleared hyperpolarized mitochondria, increased cellular oxidative status and defective lysosomal acidification. Under these conditions, the antigen presenting capacity of human monocytes is increased and depends on autophagic alterations. Further studies will address whether deregulated autophagy/mitophagy completion is involved in the generation of an endogenous source of self antigens and whether this leads to SLE characteristic autoimmune phenotype of monocytes.
Resting B cell dependence on the B cell antigen receptor (BCR) has been attributed solely to its signaling competence. We have recently shown that the presence of the BCR is vital for endoplasmic reticulum (ER) homeostasis and mitochondrial function both in primary B cells and Burkitt lymphoma (BL) cell lines. Unexpectedly, in BL Ramos cells this role has been shown to be independent of BCR signals from the cell membrane. Now, we provide evidence that also in mouse resting B cells ER-resident immunoglobulin (Ig) heavy chains control ER homeostasis, calcium storage and mitochondrial homeostasis through ER-mitochondria contacts. These findings demonstrate that BCR expression shapes cellular fitness already at the stage of assembly in the ER and uncover a new layer of B cell dependence on the production of Ig heavy chains in the ER. Sensing protein expression in the ER, with counterselection of compromised cells, might well operate also in other differentiated cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.